Preliminary Results/Change in ForecastBRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/2530-Apr-2025 / 17:54 ...

Edema is a medical condition characterized by the accumulation of excess fluid in the body’s tissues, leading to swelling and ...

Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

The Interventional Oncology Market is poised for significant growth, projected to reach USD 3.9 billion by 2025, expanding at ...

Hiring the right Laravel development company is not just about technical skills. It's about finding a team that understands ...

Introduction: The Convergence of AI and Life SciencesTraditionally, drug discovery is a time-consuming and costly process, ...

NCIMB Limited ("NCIMB"), a leading microbiology services provider and owner of the UK’s largest industrial, food and marine bacterial culture collection, has secured a £1.7m investment from the ...

Cycuria aims to revolutionise treatment of hard-to-treat blood cancers with a first-in-class protein-based therapeutic approach specifically targeting both tumour cells and tumour stem cells·    ...

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation ...

The Novo Nordisk Foundation today announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen ...

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans ...